A Look At Hologic (HOLX) Valuation As Shares Reenter Investor Focus

Why Hologic Stock Is Back on Investors’ Radar

Hologic (HOLX) is drawing fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with the company’s fundamentals and recent share performance.

The stock last closed at US$75.35, with total return readings ranging from a small 1 day decline to a modest gain over the past 3 months and a stronger move over the past year.

See our latest analysis for Hologic.

For Hologic, a 1 year total shareholder return of 15.51% alongside a 3 year total shareholder return decline of 5.39% suggests that recent momentum has improved, even if longer term holders have experienced a flatter journey.

If this healthcare move has your attention, it could be a good moment to size up other medical technology names through our screener of 28 healthcare AI stocks.

Hologic now trades close to analyst targets yet carries an estimated 31% intrinsic discount, with recent revenue and net income growth in the background. Is the stock still undervalued, or is the market already pricing in future gains?

Most Popular Narrative: 1.6% Undervalued

Hologic’s most followed valuation narrative pins fair value at about $76.60, just above the last close of $75.35, which puts the focus firmly on the earnings and margin story behind that figure.

Operational improvements, including optimized salesforce execution, targeted end-of-life upgrades, and substantial mitigation of supply chain tariff impacts, are restoring growth momentum and efficiency while supporting EPS recovery and stabilizing or improving net margins into fiscal 2026 and beyond.

Read the complete narrative.

Curious what sits behind that fair value line? The narrative leans on steady top line expansion, thicker margins, and a future earnings multiple that assumes consistent execution. Want to see how those pieces fit together in detail?

Result: Fair Value of $76.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this fair value story can quickly look different if tariff costs remain elevated or if international pressure in markets such as China and Africa persists.

Find out about the key risks to this Hologic narrative.

Another View: Market Pricing Versus Fair Ratio

Our DCF work suggests Hologic is trading at about a 31% discount to future cash flows, yet the P/E of 30.9x sits above the fair ratio of 28.7x and roughly in line with the US Medical Equipment average of 30.9x. Is this a value gap, or a sign the market is already cautious?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of signals feels finely balanced, now is a good time to review the underlying data yourself and decide what matters most for your portfolio. You can start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this has sharpened your focus on quality and price, do not stop at a single stock. Broaden your watchlist with ideas that match your style.

• Target potential mispricings by scanning our list of 51 high quality undervalued stocks that pair solid fundamentals with discounted valuations.
• Strengthen your income stream by reviewing 16 dividend fortresses, featuring companies with higher yields that might complement growth focused holdings.
• Prioritise resilience first by checking 78 resilient stocks with low risk scores, built around businesses with lower risk profiles that could help steady your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com